Targets › CD7
18 programs from 13 companies in 22 trials: 19 Phase 1, 3 Phase 2; Oncology, Immunology; next expected readout Dec 2026.
Transmembrane glycoprotein expressed by T-cells and natural killer (NK) cells and their precursors. Plays a costimulatory role in T-cell activation upon binding to its ligand K12/SECTM1. (UniProt, P09564)
Open in Phaseline: the race on CD7, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Allotera Therapeutics | WU-CART-007 Anti-CD7 allogeneic CAR-T cell therapy | CD7 | Phase 2 | T-cell Acute Lymphoblastic Leukemia | Dec 2026 |
| PersonGen BioTherapeutics (Suzhou) | PA3-17 injection anti-CD7 CAR-T cell therapy | CD7 | Phase 2 | CD7-positive Relapsed/Refractory T Lymphoblastic Leukemia/Lymphoma | Oct 2027 |
| Institute of Hematology & Blood Diseases Hospital, China | CD7-CART anti-CD7 CAR-T cell therapy | CD7 | Phase 2 | CD7 Positive | Jan 2029 |
| Essen Biotech | CD5/CD7 CAR-T Chimeric antigen receptor T cells targeting CD5 and CD7 | CD5, CD7 | Phase 1 | T Cell Lymphoma | Dec 2026 |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | RD13-02 anti-CD7 CAR-T cell therapy | CD7 | Phase 1 | NK T-Cell Lymphoma | Dec 2026 |
| Beijing GoBroad Hospital | umbilical cord blood CD19-BCMA CAR-T cells dual-targeted CAR-T cell therapy targeting CD19 and BCMA | CD19, BCMA, CD5, CD7 | Phase 1 | Refractory Lupus Nephritis; T-Cell Non-Hodgkin Lymphoma | Apr 2027 |
| Zhejiang University | MT027 CAR-T cells CAR-T cells targeting CD7 antigen on malignant hematopoietic cells | CD7 | Phase 1 | Hematologic Diseases; B7-H3-positive Advanced Malignant Solid Tumors Advanced Primary Peritoneal Tumors or Secondary Abdominal Metastatic Malignant Solid Tumors | Apr 2027 |
| The General Hospital of Western Theater Command | CD7 CAR-T cell CD7-targeted CAR-T cell therapy | CD7 | Phase 1 | Acute-Leukemia | Dec 2027 |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | CD7-specific CAR-T Cells anti-CD7 CAR-T cell therapy | CD7 | Phase 1 | Hematologic Malignancy | Dec 2027 |
| Peking University People's Hospital | CD7-targeted CAR-T cells anti-CD7 CAR-T cell therapy | CD7 | Phase 1 | CD7+ T-ALL/LBL | Dec 2027 |
| Beijing GoBroad Hospital | Autologous CD7 CAR T-cell CD7-targeted chimeric antigen receptor T-cell therapy | CD7 | Phase 1 | T-cell Acute Lymphoblastic Leukemia | Mar 2028 |
| Beijing GoBroad Hospital | Prior-HSCT donor-derived CD7 CAR T-cell CD7-targeted chimeric antigen receptor T-cell therapy | CD7 | Phase 1 | T-cell Acute Lymphoblastic Leukemia | Mar 2028 |
| Institute of Hematology & Blood Diseases Hospital, China | supCD7 CART cells anti-CD7 CAR-T cell therapy | CD7 | Phase 1 | T Lymphoblastic Leukemia/Lymphoma | Jun 2028 |
| Institute of Hematology & Blood Diseases Hospital, China | uCD7 CART CAR-T cell therapy targeting CD7-positive cells | CD7 | Phase 1 | Acute Myeloid Leukemia (AML) | Jun 2028 |
| Bambino Gesù Hospital and Research Institute | CD7-CART01 anti-CD7 CAR-T cell therapy | CD7 | Phase 1 | T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma | Sep 2028 |
| Baylor College of Medicine | CD7.CAR/28zeta T Cells CD7-targeted chimeric antigen receptor T cell therapy | CD7 | Phase 1 | T-cell Acute Lymphoblastic Lymphoma | Dec 2028 |
| Stephan Grupp MD PhD | BEAM-201 anti-CD7 CAR-T cell therapy | CD7 | Phase 1 | T-Cell Acute Lymphoblastic Leukemia/Lymphoma | May 2029 |
| Hebei Senlang Biotechnology | SENL101 CD7-targeting CAR-T cell therapy | CD7 | Phase 1 | T-lymphoblastic Lymphoma | Aug 2038 |
T-cell Acute Lymphoblastic Leukemia (3) Refractory Lupus Nephritis (2) T-Cell Non-Hodgkin Lymphoma (2) T-Cell Acute Lymphoblastic Leukemia/Lymphoma (1) CD7+ T-ALL/LBL (1) T Cell Lymphoma (1) T-cell Acute Lymphoblastic Lymphoma (1) Hematologic Malignancy (1) Hematologic Diseases (1) B7-H3-positive Advanced Malignant Solid Tumors Advanced Primary Peritoneal Tumors or Secondary Abdominal Metastatic Malignant Solid Tumors (1) CD7-positive Relapsed/Refractory T Lymphoblastic Leukemia/Lymphoma (1) NK T-Cell Lymphoma (1)
other (17), protein or peptide (1)
Beijing GoBroad Hospital (3) Institute of Hematology & Blood Diseases Hospital, China (3) Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (2) Stephan Grupp MD PhD (1) Peking University People's Hospital (1) Essen Biotech (1) Baylor College of Medicine (1) Zhejiang University (1) PersonGen BioTherapeutics (Suzhou) (1) Bambino Gesù Hospital and Research Institute (1) Allotera Therapeutics (1) The General Hospital of Western Theater Command (1) Hebei Senlang Biotechnology (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.